田中孝尚先生の総説が、Digestion誌(Journal Citation Reports Impact Factor 2024 = 3.6)にpublishされました。

Digestion. 2025 Dec 11:1-17. doi: 10.1159/000550032. Online ahead of print.

Integrin Inhibitors for Ulcerative Colitis Treatment

Takanao Tanaka, Keiichi Tominaga, Shunsuke Kojimahara, Mimari Kanazawa, Akira Yamamiya, Takeshi Sugaya, Atsushi Irisawa

PMID: 41379729 DOI: 10.1159/000550032

Abstract
Background: Ulcerative colitis is a diffuse, non-specific inflammatory bowel disease of unknown etiology with recurrent relapse and remission. The mechanisms of immune-mediated inflammation as a pathogenesis of ulcerative colitis have been increasingly elucidated, leading to development of biological agents and low-molecular-weight agents that target specific molecules or disease processes.

Summary: Integrin inhibitors impede ulcerative colitis pathogenesis by selectively inhibiting integrin, an adhesion molecule expressed on leukocytes, thereby suppressing lymphocyte infiltration into gastrointestinal tissues and controlling excessive immune responses at the inflammation site: the intestinal tract.

Key message: This article describes the mechanism of integrin inhibitors’ action, the usefulness and positioning of vedolizumab and carotegrast methyl, which are currently available for clinical use to treat ulcerative colitis, and the status of integrin inhibitor development.

https://pubmed.ncbi.nlm.nih.gov/41379729/